REMARKS

Claim 1 was pending in the Application. Claim 1 has been cancelled without prejudice to its subsequent prosecution in this application or in related applications. Claims 2-23 have been added. Upon entry of the present Amendment, claims 2-23 are pending and presented for consideration. A copy of the pending claims are enclosed for the Examiner's convenience.

Support for new claims 2 and 13 is found throughout the Specification and at least at pages 8 and 9 and in originally-filed claim 1. Support for new claims 3 and 14 is found throughout the Specification and at least at page 4, lines 21-23. Support for new claims 4 and 15 is found throughout the Specification and at least at page 4, lines 1-5. Support for new claims 5 and 16 is found throughout the Specification and at least at page 4, lines 8-14. Support for new claims 6 and 17 is found throughout the Specification and at least at page 9, lines 13-16. Support for new claims 7 and 18 is found throughout the Specification and at least at page 8, lines 11 and 12 and at page 9, lines 13-16. Support for new claims 8 and 19 is found throughout the Specification and at least at page 4, lines 23-25. Support for new claims 9, 10, 20 and 21 is found throughout the Specification and at least at page 4, lines 27-29. Support for new claims 11 and 22 is found throughout the Specification and at least at page 4, lines 15-20.

SUMMARY

Claim 1 was pending in the Application. Claim 1 has been cancelled and claims 2-23 have been added by the present Amendment. Applicants respectfully submit that no new matter has been introduced by the present Amendment.

Applicants submit that the claims are in condition for allowance. If the Examiner believes a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the undersigned attorney would welcome the opportunity to discuss any outstanding issues and to work with the Examiner toward placing the Application in condition for allowance.

Applicants believe no fee is necessitated by the present Amendment. Nevertheless, if additional fees are due, the Commissioner is hereby authorized to charge any such fees to Attorney's Deposit Account No. 20-0531.

Respectfully submitted,



Christine C. Vito
Reg. No. 39,061

Dated: September 13, 2000

Testa, Hurwitz & Thibeault, LLP
High Street Tower
125 High Street
Boston, MA 02110
(Tel) (617) 248-7368
(Fax) (617) 248-7100

1065392-1

A method for treating sepsis in a mammal, the method comprising the step of:

(a) administering to the mammal an amount of TCF-II effective to treat sepsis.

3. The method of claim 2, wherein the therapeutic agent is administered intravenously, intramuscularly or subcutaneously.

4. The method of claim 2 comprising the additional step, prior to step (a), of

expressing a recombinant DNA encoding TCF-II in a host cell, thereby to prepare the therapeutic agent.

5. The method of claim 2, comprising the additional step, prior to step (a), of

purifying an amount of TCF-II effective to treat sepsis.

6. The method of claim 2, wherein the mammal has, or is at risk of having, sepsis caused by a burn, surgery, cancer, AIDS, radiotherapy, chemotherapy, or long-term total parenteral nutrition.

7. The method of claim 6, wherein the mammal has, or is at risk of having, sepsis caused by surgery.

8. The method of claim 2, wherein the TCF-II is administered to the mammal in conjunction with a pH conditioner, buffer or stabilizer.

9. The method of claim 2, wherein the amount of TCF-II is from about 0.6 mg to about 600 mg of TCF-II.

10. The method of claim 9, wherein the amount of TCF-II is from about 6 mg to about 60 mg of TCF-II.

11. The method of claim 2, wherein the TCF-II comprises a polysaccharide chain.

12. A method for treating sepsis in a mammal, the method comprising the step of:

    (a) administering to the mammal a therapeutic agent comprising an amount of purified hepatocyte growth factor or purified scatter factor effective to treat sepsis.

13. A method for preventing sepsis in a mammal, the method comprising the step of:

    (a) administering to the mammal an amount of TCF-II effective to prevent sepsis.

14. The method of claim 13, wherein the therapeutic agent is administered intravenously, intramuscularly or subcutaneously.

15. The method of claim 13 comprising the additional step, prior to step (a), of

    expressing a recombinant DNA encoding TCF-II in a host cell, thereby to prepare the therapeutic agent.

16. The method of claim 13, comprising the additional step, prior to step (a), of

    purifying an amount of TCF-II effective to prevent sepsis.

17. The method of claim 13, wherein the mammal is at risk of having sepsis caused by a burn, surgery, cancer, AIDS, radiotherapy, chemotherapy, or long-term total parenteral nutrition.

18. The method of claim 17, wherein the mammal is at risk of having sepsis caused by surgery.

19. The method of claim 13, wherein the TCF-II is administered to the mammal in conjunction with a pH conditioner, buffer or stabilizer.

20. The method of claim 13, wherein the amount of TCF-II is from about 0.6 mg to about 600 mg of TCF-II.

21. The method of claim 20, wherein the amount of TCF-II is from about 6 mg to about 60 mg of TCF-II.

22. The method of claim 13, wherein the TCF-II comprises a polysaccharide chain.

23. A method for preventing sepsis in a mammal, the method comprising the step of:

(a) administering to the mammal a therapeutic agent comprising an amount of purified hepatocyte growth factor or purified scatter factor effective to prevent sepsis.